Kuo-Kai Chin
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kuo-Kai Chin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:47 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07392242 · A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT07356154 · A Study of Revumenib and Mezigdomide in People With LeukemiaMemorial Sloan Kettering Cancer Center · recruiting · Leukemia, Acute Leukemia, Relapse Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:47 UTC. The ranking covers the 200 most relevant of 178 PubMed records, and a shared surname and initials can bring in a namesake. All 178 on PubMed
- 1,916 citationsRCR 63.7
- 983 citationsRCR 35.4
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.Lancet Oncol · 2010980 citationsRCR 22.0
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.Lancet Oncol · 2016968 citationsRCR 31.1
- Selexipag for the Treatment of Pulmonary Arterial Hypertension.N Engl J Med · 2015821 citationsRCR 31.7
- Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.Breast Cancer Res Treat · 2018630 citationsRCR 20.9
- Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.J Clin Oncol · 2017486 citationsRCR 15.1
- Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.Ann Oncol · 2015450 citationsRCR 15.4
- 445 citationsRCR 11.3
- Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.J Clin Oncol · 2013399 citationsRCR 11.2